1
项与 LUCAR-G39P(Nanjing Legend Biotechnology) 相关的临床试验A Phase I, Open-label Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LUCAR-G39P, a Dual-targeted Cell Preparation Targeting CD19/CD20, in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
A phase I, open-label clinical study to evaluate the safety, tolerability, and efficacy of LUCAR-G39P, a dual-targeted cell preparation targeting CD19/CD20, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
100 项与 LUCAR-G39P(Nanjing Legend Biotechnology) 相关的临床结果
100 项与 LUCAR-G39P(Nanjing Legend Biotechnology) 相关的转化医学
100 项与 LUCAR-G39P(Nanjing Legend Biotechnology) 相关的专利(医药)
100 项与 LUCAR-G39P(Nanjing Legend Biotechnology) 相关的药物交易